CA
DMAA

Crossingbridge Advisors’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Crossingbridge Advisors’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-850,000
Closed -$1.3M – 112
2025
Q1 		$1.3M Buy
+850,000
New +$8.5M 0.68% 31

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.69% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Crossingbridge Advisors's DMAA Position: Q2 2025 in Review

Crossingbridge Advisors sold out of Drugs Made In America Acquisition Corp (DMAA) in Q2 2025, closing a stake of 850,000 shares — an estimated $1.3M sold.

Crossingbridge Advisors first reported a position in DMAA in Q1 2025 and held it in 1 quarter. The position peaked at $1.3M in Q1 2025. 32 funds tracked by Wall St. Rank hold DMAA as of Q2 2025.

  • Crossingbridge Advisors reported no remaining Drugs Made In America Acquisition Corp position as of Q2 2025 after selling out during the quarter.
  • Crossingbridge Advisors sold 850,000 Drugs Made In America Acquisition Corp shares in Q2 2025, an estimated $1.3M.
  • Crossingbridge Advisors first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and held it in 1 quarter.
  • Crossingbridge Advisors's Drugs Made In America Acquisition Corp position peaked at $1.3M in Q1 2025.
  • 32 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2025.

Based on Crossingbridge Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.